In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model

Du,Xiaohui; Jin,Runsen; Ning,Ning; Li,Li; Wang,Quansheng; Liang,Wentao; Liu,Juchao; Xu,Yingxin

doi:10.3892/or.2012.2013

In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model

Authors:
- Xiaohui Du
- Runsen Jin
- Ning Ning
- Li Li
- Quansheng Wang
- Wentao Liang
- Juchao Liu
- Yingxin Xu
View Affiliations

Affiliations: General Surgery Department, Hainan Branch of Chinese PLA General Hospital, Sanya, Hainan, P.R. China, Institute of General Surgery, Chinese PLA General Hospital, Beijing, P.R. China
Published online on: September 3, 2012 https://doi.org/10.3892/or.2012.2013
Pages: 1743-1749

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adoptive cellular transfer has been employed for cancer immunotherapy, including patients with gastric cancer. However, little is known about the distribution of effector cells after their injection via different pathways. In this study, we used human gastric cancer cells (BGC823) tagged with enhanced green fluorescent protein (EGPF) to establish a subcutaneous gastric cancer model in nude mice. Cytokine-induced killer (CIK) cells and cytotoxic T lymphocytes (CTLs) were generated from human peripheral blood and labeled with red fluorescent PKH26. A portion of CIK cells was armed with CEA/CD3-bispecific single-chain antibody. When CIK cells were injected into nude mice with established subcutaneous gastric cancer via peritumoral (p.t.), intravenous (i.v.) and intraperitoneal (i.p.) infusion respectively, the distribution of cells was observed using a live fluorescence imaging system. We found that only a very small number of CIK cells could travel to the tumor site after i.p. or i.v. infusion, and they inhibited subcutaneous tumor growth in vivo only immediately following injection. In contrast, p.t. injection resulted in a significantly higher accumulation of CIK cells at the tumor site for 48 hours and mediated the greatest tumor inhibition compared with the other two injection methods. In addition, we compared the antitumor activity of CIK, CEA/CD3-bscAb-CIK and CTL cells in vitro and in vivo after p.t. injection. Among the three types of immune cells, CTLs demonstrated the strongest antitumor activity both in vitro and in vivo. CEA/CD3-bispecific single chain antibody could effectively link T lymphocytes and tumor cells expressing CEA, and resulted in significantly higher accumulation of CIK cells at the tumor site compared with the parental CIK cells. This study indicates that peritumoral injection of immune effector cells by minimally invasive surgical procedures represents an effective delivery method of adoptive cellular immunotherapy. Tumor-specific immune cells, such as CTLs, are a better choice of effector cells than CIKs in cellular immunotherapy. Furthermore, CD3+ immune cells armed with the CEA/CD3-bispecific single chain antibody could more effectively travel to and accumulate at the site of tumors expressing CEA, such as gastric cancer.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
2	Kim HM, Kang JS, Lim J, et al: Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res. 32:781–787. 2009. View Article : Google Scholar
3	Klebanoff CA, Gattinoni L, Palmer DC, et al: Determinants of successful CD8⁺ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res. 17:5343–5352. 2011.PubMed/NCBI
4	Marcus A and Eshhar Z: Tumor-specific allogeneic cells for cancer therapy. Expert Opin Biol Ther. 11:1551–1554. 2011. View Article : Google Scholar : PubMed/NCBI
5	June CH: Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 117:1466–1476. 2007. View Article : Google Scholar : PubMed/NCBI
6	Di Stasi A, Tey SK, Dotti G, et al: Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 365:1673–1683. 2011.PubMed/NCBI
7	Zhong JH, Ma L, Wu LC, et al: Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract. 66:21–27. 2012. View Article : Google Scholar : PubMed/NCBI
8	Toh U, Fujii T, Mishima M, et al: Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer. Gan To Kagaku Ryoho. 34:1931–1933. 2007.(In Japanese).
9	Linn YC and Hui KM: Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010:4357452010.PubMed/NCBI
10	Sangiolo D: Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2:363–368. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ma Y, Zhang Z, Tang L, et al: Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy. 14:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wright SE, Rewers-Felkins KA, Quinlin IS, et al: Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother. 35:196–204. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hickey MJ, Malone CC, Erickson KE, et al: Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas. Am J Transl Res. 4:114–126. 2012.PubMed/NCBI
14	Yang M, Baranov E, Jiang P, et al: Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA. 97:1206–1211. 2000. View Article : Google Scholar : PubMed/NCBI
15	Chishima T, Miyagi Y, Wang X, et al: Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res. 57:2042–2047. 1997.PubMed/NCBI
16	Heim R, Cubitt AB and Tsien RY: Improved green fluorescence. Nature. 373:663–664. 1995. View Article : Google Scholar : PubMed/NCBI
17	Kaneko K, Yano M, Tsujinaka T, et al: Establishment of a visible peritoneal micrometastatic model from a gastric adenocarcinoma cell line by green fluorescent protein. Int J Oncol. 16:893–898. 2000.PubMed/NCBI
18	Kaneko K, Yano M, Yamano T, et al: Detection of peritoneal micrometastases of gastric carcinoma with green fluorescent protein and carcinoembryonic antigen promoter. Cancer Res. 61:5570–5574. 2001.PubMed/NCBI
19	Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
20	Linn YC, Lau LC and Hui KM: Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 116:78–86. 2002. View Article : Google Scholar : PubMed/NCBI
21	Lopez RD, Waller EK, Lu PH and Negrin RS: CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56⁺ T cells. Cancer Immunol Immunother. 49:629–640. 2001. View Article : Google Scholar : PubMed/NCBI
22	Niam M, Linn YC, Fook Chong S, et al: Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol. 39:897–903. 2011. View Article : Google Scholar
23	Hazelrigg MR, Hirsch JI and Merchant RE: Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma-bearing rat. J Neurooncol. 60:143–150. 2002. View Article : Google Scholar
24	Skitzki J, Craig RA, Okuyama R, et al: Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res. 64:2183–2191. 2004. View Article : Google Scholar
25	Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH and Negrin RS: Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 101:640–648. 2003. View Article : Google Scholar
26	Nishimura R, Baker J, Beilhack A, et al: In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 112:2563–2574. 2008. View Article : Google Scholar
27	Brandau S and Bohle A: Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol. 39:518–524. 2001. View Article : Google Scholar : PubMed/NCBI
28	Akagi J, Takai E, Tamori Y and Ogawa M: CD3⁺CD56⁺CD8⁺ cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients. Int J Oncol. 19:561–566. 2001.
29	Nagaraj S, Ziske C and Schmidt-Wolf IG: Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Ther. 2:122004. View Article : Google Scholar : PubMed/NCBI
30	Marten A, Renoth S, von Lilienfeld-Toal M, et al: Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica. 86:1029–1037. 2001.
31	Ziske C, Marten A, Schottker B, et al: Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. Mol Ther. 3:54–60. 2001. View Article : Google Scholar : PubMed/NCBI
32	van Spriel AB, van Ojik HH and van De Winkel JG: Immunotherapeutic perspective for bispecific antibodies. Immunol Today. 21:391–397. 2000.PubMed/NCBI
33	Flieger D, Kufer P, Beier I, Sauerbruch T and Schmidt-Wolf IG: A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3⁺CD56⁺ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells. Cancer Immunol Immunother. 49:441–448. 2000. View Article : Google Scholar : PubMed/NCBI
34	Lutterbuese R, Raum T, Kischel R, et al: Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 32:341–352. 2009. View Article : Google Scholar : PubMed/NCBI
35	Savage P, Millrain M, Dimakou S, Stebbing J and Dyson J: Expansion of CD8⁺ cytotoxic T cells in vitro and in vivo using MHC class I tetramers. Tumour Biol. 28:70–76. 2007.
36	Morishima N, Mizoguchi I, Okumura M, et al: A pivotal role for interleukin-27 in CD8⁺ T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol. 2010:6054832010. View Article : Google Scholar : PubMed/NCBI
37	Yee C, Thompson JA, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8⁺ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 99:16168–16173. 2002.PubMed/NCBI
38	Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J and Andreesen R: Phase I study of adoptive T-cell therapy using antigen-specific CD8⁺ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 24:5060–5069. 2006. View Article : Google Scholar : PubMed/NCBI
39	Butler MO, Lee JS, Ansen S, et al: Long-lived antitumor CD8⁺ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 13:1857–1867. 2007.PubMed/NCBI
40	Yamaguchi Y, Ohshita A, Hironaka K, et al: Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells. Oncol Rep. 16:165–169. 2006.